ArticleCancer chemotherapy and pharmacology2023

A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.

Richard Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.